Day: September 14, 2022

WASHINGTON, Sept. 14, 2022 (GLOBE NEWSWIRE) — The Sabin Vaccine Institute today announced it is receiving an additional $21.8 million under an existing contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services. These funds advance development of a vaccine against Marburg virus disease, a virus that is related to Ebola Zaire which killed 2200 people during the last major outbreak that ended in 2020.

The Sabin Marburg vaccine is the only candidate currently slated for a Phase 2 clinical trial. Marburg is among the world’s deadliest viruses, resulting in the death of approximately half the people the virus infects. Currently, there are no approved vaccines or treatments for the disease. As recently as July this year, two people in Ghana died after being infected with Marburg virus, reinforcing the urgent need for medical therapies.

The latest tranche of funds enables Sabin to conduct a randomized, blinded, placebo-controlled clinical trial among adults in the U.S. to further evaluate the safety and the efficacy of the Marburg vaccine candidate and advance non-clinical vaccine dosing studies. The Phase 2 clinical trial in the U.S. will begin after Sabin has initiated a same-stage trial in Africa, currently scheduled for 2023. Sabin will also undertake a non-clinical study on the vaccine candidate during this phase.

“Beginning Phase 2 clinical trials for the Marburg vaccine is a pivotal milestone for us and we appreciate BARDA’s continued confidence in our work and support for this critical next step,” says Sabin Chief Executive Officer Amy Finan. “Vaccines remain our best bet against death and disability from deadly viruses. I am hopeful that in the years ahead, we can offer this life-saving vaccine to every person who needs it.”

In 2019, BARDA awarded Sabin a multi-year contract valued at $128 million to further the development of vaccines against two lethal viruses: Marburg and Ebola Sudan. With BARDA now exercising the latest option of that contract, Sabin’s Ebola and Marburg Research & Development program, to date, has been awarded $98.6 million.

BARDA is part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services. This project has been funded in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority, under contract number 75A50119C000555.

Learn more about Sabin’s Marburg and Ebola Sudan Program.

About the Sabin Vaccine Institute

The Sabin Vaccine Institute is a leading advocate for expanding vaccine access and uptake globally, advancing vaccine research and development, and amplifying vaccine knowledge and innovation. Unlocking the potential of vaccines through partnership, Sabin has built a robust ecosystem of funders, innovators, implementers, practitioners, policy makers and public stakeholders to advance its vision of a future free from preventable diseases. As a non-profit with more than two decades of experience, Sabin is committed to finding solutions that last and extending the full benefits of vaccines to all people, regardless of who they are or where they live. At Sabin, we believe in the power of vaccines to change the world. For more information, visit www.sabin.org and follow us on Twitter, @SabinVaccine.

About Ebola Sudan and Marburg

Ebola Sudan and Marburg are members of the filovirus family. Both can cause severe hemorrhagic fever in humans and nonhuman primates. No therapeutic treatment of the hemorrhagic fevers caused by filoviruses has been licensed to date. Marburg and Ebola viruses are transmitted to humans by infected animals, particularly fruit bats. Once a human is infected, the virus can spread to others through close personal contact or contact with bodily fluids. Isolation of infected people is currently the centerpiece of filovirus control.

Marburg was the first filovirus to be recognized in 1967 when outbreaks of hemorrhagic fever were reported in a few Europe-based laboratories including in the town of Marburg, Germany. Ebola was identified in 1976 when two simultaneous outbreaks occurred in northern Zaire (now the DRC) in a village near the Ebola River and southern Sudan. The outbreaks involved what eventually proved to be two different species of Ebola virus; both were named after the nations in which they were discovered.

Media contact:

Rajee Suri
press@sabin.org

Responds to regional demand for low latency performance and complies with offshore data routing requirements

MAHWAH, N.J., Sept. 14, 2022 (GLOBE NEWSWIRE) — Radware^® (NASDAQ: RDWR), a leading provider of cyber security and application delivery solutions, announced the launch of a new cloud security center in the United Arab Emirates. Located in Dubai, the facility will reduce latency for in-region traffic and offer customers faster mitigation response times against denial-of-service attacks, web application attacks, malicious bot traffic, and attacks on APIs. It will also mitigate compliance processes involved in offshore routing.

The Dubai addition complements Radware’s existing cloud security network. Today, the network includes over 10Tbps of mitigation capacity across more than 50 security centers located around the globe.

“As part of our strategic cloud services initiative, we continue to accelerate cloud innovation to provide our customers with the highest level of cyber security services,” said Haim Zelikovsky, vice president of cloud security services for Radware. “This includes increasing the fighting capacity of our cloud infrastructure to help our customers manage the increasing complexity and sheer volume of cyberattacks with as little disruption as possible.”

According to Radware’s First Half 2022 Global Threat Analysis Report, the first six months of 2022 saw a dramatic increase in cyberattacks across the globe. The number of DDoS attacks climbed 203% and malicious web application transactions grew by 38% compared to the same period last year.

“The new site in Dubai fills a growing demand for a local security presence that can deliver rapid response times with accuracy for organizations in the public and private sector,” said Nikhil Karan Taneja, Radware’s vice president and managing director for India, the Middle East, and South Asia. “The launch of the center underscores our ongoing commitment to delivering state-of-the-art cyber protection and scaling our capacity in a way that will benefit the whole region.”

About Radware
Radware^® (NASDAQ: RDWR) is a global leader of cyber security and application delivery solutions for physical, cloud, and software defined data centers. Its award-winning solutions portfolio secures the digital experience by providing infrastructure, application, and corporate IT protection, and availability services to enterprises globally. Radware’s solutions empower enterprise and carrier customers worldwide to adapt to market challenges quickly, maintain business continuity, and achieve maximum productivity while keeping costs down. For more information, please visit the Radware website.

Radware encourages you to join our community and follow us on: Facebook, LinkedIn, Radware Blog, Twitter, YouTube, and Radware Mobile for iOS and Android.

©2022 Radware Ltd. All rights reserved. Any Radware products and solutions mentioned in this press release are protected by trademarks, patents, and pending patent applications of Radware in the U.S. and other countries. For more details, please see: https://www.radware.com/LegalNotice/. All other trademarks and names are property of their respective owners.

Radware believes the information in this document is accurate in all material respects as of its publication date. However, the information is provided without any express, statutory, or implied warranties and is subject to change without notice.

The contents of any website or hyperlinks mentioned in this press release are for informational purposes and the contents thereof are not part of this press release.

Safe Harbor Statement
This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements made herein that are not statements of historical fact, including statements about Radware’s plans, outlook, beliefs, or opinions, are forward-looking statements. Generally, forward-looking statements may be identified by words such as “believes,” “expects,” “anticipates,” “intends,” “estimates,” “plans,” and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could.” For example, when we say that we have an ongoing commitment to scale our capacity, we are using a forward-looking statement. Because such statements deal with future events, they are subject to various risks and uncertainties, and actual results, expressed or implied by such forward-looking statements, could differ materially from Radware’s current forecasts and estimates. Factors that could cause or contribute to such differences include, but are not limited to: the impact of global economic conditions and volatility of the market for our products; natural disasters and public health crises, such as the coronavirus disease 2019 (COVID-19) pandemic; a shortage of components or manufacturing capacity could cause a delay in our ability to fulfill orders or increase our manufacturing costs; our business may be affected by sanctions, export controls, and similar measures, targeting Russia and other countries and territories, as well as other responses to Russia’s military conflict in Ukraine, including indefinite suspension of operations in Russia and dealings with Russian entities by many multi-national businesses across a variety of industries; our ability to successfully implement our strategic initiative to accelerate our cloud business; our ability to expand our operations effectively; timely availability and customer acceptance of our new and existing solutions; risks and uncertainties relating to acquisitions or other investments; the impact of economic and political uncertainties and weaknesses in various regions of the world, including the commencement or escalation of hostilities or acts of terrorism; intense competition in the market for cyber security and application delivery solutions and in our industry in general, and changes in the competitive landscape; changes in government regulation; outages, interruptions, or delays in hosting services or our internal network system; compliance with open source and third-party licenses; the risk that our intangible assets or goodwill may become impaired; our dependence on independent distributors to sell our products; long sales cycles for our solutions; changes in foreign currency exchange rates; undetected defects or errors in our products or a failure of our products to protect against malicious attacks; the availability of components and manufacturing capacity; the ability of vendors to provide our hardware platforms and components for our main accessories; our ability to protect our proprietary technology; intellectual property infringement claims made by third parties; changes in tax laws; our ability to realize our investment objectives for our cash and liquid investments; our ability to attract, train, and retain highly qualified personnel; and other factors and risks over which we may have little or no control. This list is intended to identify only certain of the principal factors that could cause actual results to differ. For a more detailed description of the risks and uncertainties affecting Radware, refer to Radware’s Annual Report on Form 20-F, filed with the Securities and Exchange Commission (SEC), and the other risk factors discussed from time to time by Radware in reports filed with, or furnished to, the SEC. Forward-looking statements speak only as of the date on which they are made and, except as required by applicable law, Radware undertakes no commitment to revise or update any forward-looking statement in order to reflect events or circumstances after the date any such statement is made. Radware’s public filings are available from the SEC’s website at www.sec.gov or may be obtained on Radware’s website at www.radware.com.

Media Contact:
Gerri Dyrek
Radware
Gerri.Dyrek@radware.com

WASHINGTON, 14 sept. 2022 (GLOBE NEWSWIRE) —  Le Sabin Vaccine Institute a annoncé aujourd’hui avoir reçu 21,8 millions de dollars supplémentaires dans le cadre d’un contrat existant avec la Biomedical Advanced Research and Development Authority (BARDA), qui fait partie de l’Administration pour la préparation et la réponse stratégiques du Département de la Santé et des Services sociaux des États-Unis. Ces fonds font progresser le développement d’un vaccin contre la maladie à virus Marburg, un virus lié au virus Ebola-Zaïre qui a tué 2 200 personnes lors de la dernière épidémie majeure qui a pris fin en 2020.

Le vaccin de Sabin contre le virus Marburg est le seul candidat actuellement prévu pour un essai clinique de phase 2. Marburg fait partie des virus les plus mortels au monde, entraînant la mort d’environ la moitié des personnes infectées. Il n’existe actuellement aucun vaccin ou traitement approuvé pour lutter contre cette maladie. Pas plus tard qu’en juillet de cette année, deux personnes sont mortes au Ghana après avoir été infectées par le virus Marburg, renforçant ainsi le besoin urgent de thérapies médicales.

La dernière tranche de fonds permet à Sabin de mener un essai clinique randomisé, en aveugle et contrôlé par placebo chez des adultes aux États-Unis afin d’évaluer davantage l’innocuité et l’efficacité de son vaccin candidat contre le virus Marburg et de faire progresser des études de posologie de vaccin non cliniques. L’essai clinique de phase 2 aux États-Unis commencera après le lancement par Sabin d’un essai de même phase en Afrique, actuellement prévu pour 2023. Sabin entreprendra également une étude non clinique sur son vaccin candidat au cours de cette phase.

« Le début des essais cliniques de phase 2 pour le vaccin contre le virus Marburg constitue une étape cruciale pour nous et nous apprécions la confiance continue de la BARDA dans notre travail et son soutien pour cette prochaine étape cruciale », a déclaré Amy Finan, présidente-directrice générale de Sabin. « Les vaccins restent notre meilleur pari contre la mort et le handicap dus à des virus mortels. J’espère que dans les années à venir, nous pourrons offrir ce vaccin vital à toutes les personnes qui en ont besoin. »

En 2019, la BARDA a attribué à Sabin un contrat pluriannuel d’une valeur de 128 millions de dollars pour poursuivre le développement de vaccins contre deux virus mortels : Marburg et Ebola-Soudan. La BARDA exerçant désormais la dernière option de ce contrat, le programme de recherche et développement de Sabin contre les virus Ebola et Marburg, a reçu à ce jour 98,6 millions de dollars.

La BARDA fait partie de l’Administration pour la préparation et la réponse stratégiques du Département de la Santé et des Services sociaux des États-Unis. Ce projet a été financé en totalité ou en partie par des fonds fédéraux du Département de la Santé et des Services sociaux, l’Administration pour la préparation et la réponse stratégiques et la Biomedical Advanced Research and Development Authority, sous le contrat numéro 75A50119C000555.

Renseignements complémentaires sur le programme de Sabin dédié aux virus Marburg et Ebola-Soudan.

À propos du Sabin Vaccine Institute

Le Sabin Vaccine Institute est l’un des principaux défenseurs de l’élargissement de l’accès aux vaccins et de leur adoption à l’échelle mondiale, de l’avancement de la recherche et du développement de vaccins et de l’amplification des connaissances et de l’innovation en matière de vaccins. Libérant le potentiel des vaccins par le partenariat, Sabin a bâtit un écosystème robuste de bailleurs de fonds, innovateurs, agents de mise en œuvre, praticiens, décideurs politiques et parties prenantes publiques pour faire avancer sa vision d’un avenir où les maladies évitables ont enfin disparu. En tant qu’organisation sans but lucratif comptant plus de deux décennies d’expérience, Sabin s’est engagée à trouver des solutions qui durent et à étendre tous les bienfaits des vaccins à l’ensemble des individus, peu importe qui ils sont et où ils résident. Chez Sabin, nous sommes convaincus que les vaccins ont le pouvoir de changer le monde. Pour de plus amples informations, rendez-vous sur le site www.sabin.org et suivez-nous sur Twitter, @SabinVaccine.

À propos des virus Ebola-Soudan et Marburg

Ebola-Soudan et Marburg font partie de la famille des filovirus. Les deux peuvent causer des fièvres hémorragiques sévères chez l’humain et les primates non humains. Aucun traitement thérapeutique des fièvre hémorragiques provoquées par les filovirus n’a été autorisé à ce jour. Les virus Marburg et Ebola sont transmis aux humains par des animaux infectés, en particulier les chauves-souris frugivores. Une fois qu’un être humain est infecté, ces virus peuvent se propager à d’autres par le biais d’un contact personnel étroit ou d’un contact avec des fluides corporels. L’isolation des personnes infectées constitue actuellement la principale stratégie pour contrôler les filovirus.

Marburg a été le premier filovirus à être reconnu en 1967 lorsque des épidémies de fièvre hémorragique ont été signalées dans plusieurs laboratoires basés en Europe, y compris dans la ville de Marbourg, en Allemagne. Le virus Ebola a été identifié en 1976 lorsque deux épidémies se sont produites simultanément dans le nord du Zaïre (devenu la RDC), dans un village près de la rivière Ebola, et dans le sud du Soudan. Ces épidémies ont impliqué ce qui s’est finalement avéré être deux espèces différentes de virus Ebola ; chacune devant son nom à la nation dans laquelle elle a été découverte.

Contact pour les médias :

Rajee Suri
press@sabin.org